228 results on '"Diamond, Merle"'
Search Results
2. Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review
3. Eptinezumab treatment was associated with longer interictal headache/migraine periods which corresponded to greater improvements in patient-reported quality of life measures
4. Real-world Evidence of Adding Atogepant to OnabotulinumtoxinA for Control of Chronic Migraine: A Retrospective Chart Review (P4-12.001)
5. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
6. Safety and Tolerability Results of Atogepant for the Preventive Treatment of Episodic Migraine From a 40-Week, Open-Label Multicenter Extension of the Phase 3 ADVANCE Trial
7. Approach to the Identification and Differentiation of Migraine
8. sj-pdf-3-cep-10.1177_03331024221128250 - Supplemental material for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
9. sj-pdf-4-cep-10.1177_03331024221128250 - Supplemental material for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
10. sj-pdf-6-cep-10.1177_03331024221128250 - Supplemental material for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
11. sj-pdf-2-cep-10.1177_03331024221128250 - Supplemental material for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
12. sj-pdf-5-cep-10.1177_03331024221128250 - Supplemental material for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
13. Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
14. Diagnosing and Understanding Adult Headache
15. Correction to: Real‑World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review
16. Evaluation of the Long-Term Safety and Tolerability of Oral Atogepant 60 Mg Once Daily for Preventive Treatment of Migraine: A Phase 3, 40-Week, Multicenter Extension to the Advance Trial (P3-2.001)
17. List of Contributors
18. Headache Clinics
19. Gender-Based Issues in Headache
20. Migraine Frequency and Health Utilities: Findings from a Multisite Survey
21. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
22. Migraine During Pregnancy: Options for Therapy
23. Topiramate for migraine prevention
24. Emergency room treatment of migraine headache
25. Sumatriptan–Naproxen Sodium for Menstrual Migraine and Dysmenorrhea: Satisfaction, Productivity, and Functional Disability Outcomes
26. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2
27. Use of the Emergency Department for Severe Headache. A Population-Based Study
28. Initiating and optimizing acute therapy for migraine: The role of patient-centered stratified care
29. Additional file 1 of Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
30. Efficacy and Tolerability of Coadministration of Rizatriptan and Acetaminophen vs Rizatriptan or Acetaminophen Alone for Acute Migraine Treatment
31. Botulinum Toxin Type A in the Treatment of Chronic Migraine Without Medication Overuse
32. Characteristics of Migraine Attacks and Responses to Almotriptan Treatment: A Comparison of Menstrually Related and Nonmenstrually Related Migraines
33. Headache
34. Open-Label, Long-Term Tolerability of Naratriptan for Short-Term Prevention of Menstrually Related Migraine
35. Sumatriptan/Naproxen Sodium for Migraine: Efficacy, Health Related Quality of Life, and Satisfaction Outcomes
36. Effect of Pain Intensity and Time to Administration on Responsiveness to Almotriptan: Results from AXERT® 12.5 mg Time Versus Intensity Migraine Study (AIMS)
37. Optimizing migraine therapy: evidence-based and patient-centered care
38. Acetaminophen, Aspirin, and Caffeine Versus Sumatriptan Succinate in the Early Treatment of Migraine: Results From the ASSET Trial—A Comment
39. Topiramate Improves Health-Related Quality of Life When Used to Prevent Migraine
40. Treating Early Versus Treating Mild: Timing of Migraine Prescription Medications Among Patients With Diagnosed Migraine
41. Migraine Therapy: A Survey of Pharmacistsʼ Knowledge, Attitudes, and Practice Patterns
42. Migraine Treatment With Rizatriptan and Non-Triptan Usual Care Medications: A Pharmacy-Based Study
43. Effectiveness of Eletriptan in Acute Migraine: Primary Care for Excedrin Nonresponders
44. Recognition and intervention in patients with migraine
45. Evidence-Based Assessment of Pregnancy Outcome After Sumatriptan Exposure
46. Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II
47. Migraine Diagnosis and Treatment: Results From the American Migraine Study II
48. Migraine: A Diagnostic Dilemma in the Emergency Department
49. Divalproex in the Long-term Treatment of Chronic Daily Headache
50. Early Impact of Eptinezumab on the Health-Related Quality of Life (HRQoL) of Patients with Episodic or Chronic Migraine: SF-36 Analysis Across the Spectrum of Migraine (P1.10-025)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.